Skip to main content
MedPathMedPath Home
Clinical Trials/NCT00799942
NCT00799942
Terminated
Phase 2

Long-term Open-label Extension Study to Assess the Safety, Tolerability, and Efficacy of Neramexane Mesylate in Congenital Idiopathic Nystagmus and Acquired Nystagmus

Merz Pharmaceuticals GmbH1 site in 1 country48 target enrollmentMay 2009
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsNystagmus, CongenitalNystagmus, AcquiredMultiple Sclerosis
DrugsNeramexane mesylate

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Nystagmus, Congenital
Sponsor
Merz Pharmaceuticals GmbH
Enrollment
48
Locations
1
Primary Endpoint
Long-term safety, Visual acuity
Status
Terminated
Last Updated
15 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

The purpose of this study is to investigate the long-term safety, tolerability and efficacy of neramexane mesylate in the treatment of congenital idiopathic nystagmus (CIN). In addition, a subgroup of multiple sclerosis (MS) patients suffering from acquired nystagmus will be included.

Registry
clinicaltrials.gov
Start Date
May 2009
End Date
TBD
Last Updated
15 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •patients who has succesfully completed the lead-in study MRZ 92579-0707/1

Exclusion Criteria

  • •Occurence of any major treatment-emergent adverse event or condition during the previous protocol (MRZ 92579-0707/1)

Outcomes

Primary Outcomes

Long-term safety, Visual acuity

Time Frame: Baseline, week 4, month 3, 6, 9, 12, 18, 24, 30, 36 and follow-up

Study Sites (1)

Loading locations...

Similar Trials

Terminated
Phase 3
Open-Label, Long-Term Treatment Study, to Assess the Long-Term Safety and Tolerability and Efficacy of Neramexane in Patients With Subjective TinnitusSubjective Tinnitus
NCT00827008Merz Pharmaceuticals GmbH821
Completed
Phase 3
Evaluating the Safety of Etanercept in the Treatment of Psoriasis in Adult SubjectsPsoriasis
NCT00111436Amgen912
Completed
Not Applicable
Extension Study of Original Protocol AERO C009 for Obstructive Sleep Apnea-hypopneaObstructive Sleep Apnea HypopneaObstructive Sleep ApneaOSAH
NCT00849043Ventus Medical, Inc.65
Terminated
Phase 3
A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)Primary Immune Thrombocytopenia
NCT04596995UCB Biopharma SRL43
Terminated
Phase 3
Open-label Extension for Phase 3 Clinical Trials of SimufilamAlzheimer Disease
NCT05575076Cassava Sciences, Inc.1,081